Remove 2029 Remove Competition Remove Food and Drug Administration Remove Leads
article thumbnail

Intercept receives orphan drug designation for liver disease combo therapy

Pharmaceutical Technology

The US Food and Drug Administration (FDA) has awarded an orphan drug designation to Intercept Pharmaceuticals’ fixed-dose combination of obeticholic acid and bezafibrate for the treatment of primary biliary cholangitis. This results in bile buildup in the liver and can lead to scarring. billion in 2029.

article thumbnail

Emerging Trends in Orthopedic Medical Device Industry

Medico Reach

However, this can lead to several issues, such as: Implantation resistance due to reactionary metabolism Allergic reactions to the nickel component found in stainless steel composites Widespread bone destruction due to immunological responses to cobalt particles. billion by 2029. The US-based Enovis is leading this new development.

Medical 98
article thumbnail

Emerging Trends in Orthopedic Medical Device Industry

Medico Reach

However, this can lead to several issues, such as: Implantation resistance due to reactionary metabolism Allergic reactions to the nickel component found in stainless steel composites Widespread bone destruction due to immunological responses to cobalt particles. billion by 2029. The US-based Enovis is leading this new development.

Medical 52